RSS Feed
Tags
adaptive trials advertising advisory committees best practices biologics biosimilar biotech BLA cancer Cato BioVentures Cato Research CBER CDER CDRH clinical trials CMC conference DDMAC DIA drug development eCTD efficacy FDA GlobalSubmit guest post guidance IND inspections medical devices NDA NIH nonclinical research oncology outsourcing personalized medicine postmarketing protocol safety slides Social Media statistical analysis transparency venture capital warning letters webinarCategories
Archives
Links
Follow us on Twitter!
- Featured yesterday at Fierce Biotech IT - Cato lists five keys to success in adaptive trials http://bit.ly/aHry0A about 16 hours ago from TweetDeck
- RT @reuters: "Outgunned FDA tries to get tough with drug ads" http://bit.ly/btorHn 08:45:47 PM September 07, 2010 from web
- @MicroConstants Thanks for retweeting! 07:27:43 PM September 07, 2010 from TweetDeckin reply to MicroConstants
- New blog post: August 2010 FDA Guidances - http://ask-cato.com/mg 02:50:26 PM September 07, 2010 from WordTwit Plugin
Tag Archives: drug development
Important Steps Forward for Early Detection and Diagnose of Alzheimer’s Disease
Image via Wikipedia This is a guest post by Erik Berglund, M.D., Ph.D. Erik is a Senior Regulatory Scientist and the Associate Managing Director of Cato Research‘s San Francisco, CA office. In a recent report by Geert De Meyer of … Continue reading
Joint Statistical Meetings 2010 Retrospective: A CRO Statistician’s Perspective
Image via Wikipedia This is a guest post by John Johnson, Ph.D. John is a Senior Biostatistician and the Associate Director, Statistics at Cato Research. The Joint Statistical Meetings is often a good place to learn about emerging issues in the … Continue reading
Generic Lovenox – Moving One Step Closer to Biosimilars
We bleed from similar veins. – Tupac Shakur Lovenox is not, I repeat, not a biologic therapeutic. It is derived from a biological source (pig intestines, yum), but it is not protein-based. However, the FDA’s approval of a generic form … Continue reading
Posted in FDA, Industry News
Tagged biologics, biosimilar, drug development, FDA, generic drugs
1 Comment
Webinar Slides – Nonclinical Drug Development
Yesterday, Cato Research hosted a webinar titled, “Nonclinical Drug Development – A Successful Path Forward.” Senior Toxicologist Sharon Daily, Ph.D. gave a very informative presentation that was followed by some great questions from the audience. As promised, the slides from … Continue reading
Give Your Scientists an Edge – Partner with a CRO!
Image via Wikipedia This is a guest post by Kathy Grako, Ph.D. Kathy is a Clinical Scientist in Cato Research‘s San Diego, CA office. In the fast paced R&D world, every biotech is looking for an edge to keep them … Continue reading
Posted in Guest Posts, Regulatory Strategy, Venture Capital
Tagged biotech, clinical trials, drug development, nonclinical research, outsourcing, venture capital
Comments Off
